Identifying Barriers to Buprenorphine Treatment for Patients with Opioid Use Disorder Among Anesthesiologists and Pain Practitioners: A Survey Study

J Addict Med. 2023 Mar-Apr;17(2):e94-e100. doi: 10.1097/ADM.0000000000001066. Epub 2022 Aug 24.

Abstract

Objective: The aim of the study is to investigate barriers to opioid use disorder (OUD) care among acute and chronic pain physicians and advanced practice providers, including hypothesized barriers of lack of interest in OUD care and stigma toward this patient population.

Methods: The study used an anonymous 16-item online survey through Google Forms. Respondents were 153 health practitioners across the United States and Canada, all of whom are registered in one of several pain or anesthesia professional societies. Data were analyzed with descriptive and categorical statistics.

Results: The most common barriers include "lack of appropriate clinical environment for prescribing by both acute and chronic pain practitioners" (48%) and "lack of administrative/departmental support" (46%). A total of 32% of respondents reported that OUD care was important but they were not interested in doing more, while 28% of practitioners believed that they treat patients with OUD differently than others in a negative way. More males reported "difficulty" in treating OUD as a barrier (45% vs 25%). Chronic pain practitioners reported poor payor mix as a barrier twice as often as their acute pain colleagues. In free response, lack of multidisciplinary OUD care was a notable barrier.

Conclusions: The top barriers to OUD treatment were clinical environment, departmental support, difficulty in treating the condition, and payor mix, supporting the hypotheses. Given an OUD patient scenario, 55% of acute pain physicians and 73% of chronic pain physicians expressed a willingness to prescribe buprenorphine.

MeSH terms

  • Acute Pain* / drug therapy
  • Anesthesiologists
  • Buprenorphine* / therapeutic use
  • Chronic Pain* / drug therapy
  • Humans
  • Male
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / drug therapy
  • Practice Patterns, Physicians'
  • Surveys and Questionnaires
  • United States

Substances

  • Buprenorphine